Back to Search
Start Over
Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans — Five Veterans Affairs Medical Centers, United States, February 1–September 30, 2021
- Source :
- Morbidity and Mortality Weekly Report
- Publication Year :
- 2021
- Publisher :
- Centers for Disease Control MMWR Office, 2021.
-
Abstract
- The mRNA COVID-19 vaccines (Moderna and Pfizer-BioNTech) provide strong protection against severe COVID-19, including hospitalization, for at least several months after receipt of the second dose (1,2). However, studies examining immune responses and differences in protection against COVID-19-associated hospitalization in real-world settings, including by vaccine product, are limited. To understand how vaccine effectiveness (VE) might change with time, CDC and collaborators assessed the comparative effectiveness of Moderna and Pfizer-BioNTech vaccines in preventing COVID-19-associated hospitalization at two periods (14-119 days and ≥120 days) after receipt of the second vaccine dose among 1,896 U.S. veterans at five Veterans Affairs medical centers (VAMCs) during February 1-September 30, 2021. Among 234 U.S. veterans fully vaccinated with an mRNA COVID-19 vaccine and without evidence of current or prior SARS-CoV-2 infection, serum antibody levels (anti-spike immunoglobulin G [IgG] and anti-receptor binding domain [RBD] IgG) to SARS-CoV-2 were also compared. Adjusted VE 14-119 days following second Moderna vaccine dose was 89.6% (95% CI = 80.1%-94.5%) and after the second Pfizer-BioNTech dose was 86.0% (95% CI = 77.6%-91.3%); at ≥120 days VE was 86.1% (95% CI = 77.7%-91.3%) for Moderna and 75.1% (95% CI = 64.6%-82.4%) for Pfizer-BioNTech. Antibody levels were significantly higher among Moderna recipients than Pfizer-BioNTech recipients across all age groups and periods since vaccination; however, antibody levels among recipients of both products declined between 14-119 days and ≥120 days. These findings from a cohort of older, hospitalized veterans with high prevalences of underlying conditions suggest the importance of booster doses to help maintain long-term protection against severe COVID-19.
- Subjects :
- Male
Time Factors
Health (social science)
SARS-CoV-2
Epidemiology
Health, Toxicology and Mutagenesis
Patient Acuity
COVID-19
Vaccine Efficacy
General Medicine
Middle Aged
Antibodies, Viral
United States
Cohort Studies
Hospitalization
Health Information Management
Veterans Health Services
Humans
Female
Full Report
BNT162 Vaccine
Immunization Schedule
2019-nCoV Vaccine mRNA-1273
Aged
Veterans
Subjects
Details
- ISSN :
- 1545861X and 01492195
- Volume :
- 70
- Database :
- OpenAIRE
- Journal :
- MMWR. Morbidity and Mortality Weekly Report
- Accession number :
- edsair.doi.dedup.....06a3e0c3116549b72eba0d41245a9a0c
- Full Text :
- https://doi.org/10.15585/mmwr.mm7049a2